GPBAR1; HCAR2; | |
GAA; | |
SCN9A; SCN3A; SCN2A; SCN1A; SCN11A; SCN8A; SCN4A; | |
CA2; CA1; CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA4; CA6; | |
NR1H4; | |
ESR2; | |
AKR1B10; POLB; | |
SLCO1B3; SLCO1B1; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
Voltage-gated sodium channel | SCN9A | Sodium channel protein type IX alpha subunit | Q15858 | CHEMBL4296 |
Voltage-gated sodium channel | SCN3A | Sodium channel protein type III alpha subunit | Q9NY46 | CHEMBL5163 |
Voltage-gated sodium channel | SCN2A | Sodium channel protein type II alpha subunit | Q99250 | CHEMBL4187 |
Voltage-gated sodium channel | SCN1A | Sodium channel protein type I alpha subunit | P35498 | CHEMBL1845 |
Voltage-gated sodium channel | SCN11A | Sodium channel protein type XI alpha subunit | Q9UI33 | CHEMBL5167 |
Voltage-gated sodium channel | SCN8A | Sodium channel protein type VIII alpha subunit | Q9UQD0 | CHEMBL5202 |
Voltage-gated sodium channel | SCN4A | Sodium channel protein type IV alpha subunit | P35499 | CHEMBL2072 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0065007; biological regulation | GO:0086010; membrane depolarization during action potential | 1.167E-13 | 1.815E-10 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
BP | GO:0051179; localization | GO:0035725; sodium ion transmembrane transport | 7.053E-11 | 7.679E-08 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.768E-10 | 2.871E-07 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, NR1H4 |
MF | GO:0005215; transporter activity | GO:0005244; voltage-gated ion channel activity | 8.266E-09 | 6.666E-06 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
MF | GO:0005215; transporter activity | GO:0008381; mechanosensitive ion channel activity | 2.805E-07 | 1.566E-04 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
CC | GO:0044464; cell part | GO:0033268; node of Ranvier | 1.096E-06 | 5.435E-04 | SCN1A, SCN2A, SCN8A |
BP | GO:0051179; localization | GO:0034765; regulation of ion transmembrane transport | 1.465E-06 | 7.088E-04 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.085E-30 | 1.107E-25 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.640E-06 | 2.233E-03 | CA2, CA7 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 5.640E-06 | 2.233E-03 | GPBAR1, NR1H4 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 5.640E-06 | 2.233E-03 | GPBAR1, NR1H4 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.332E-06 | 2.233E-03 | CA2, CA4, CA9, SLCO1B1, SLCO1B3 |
BP | GO:0051179; localization | GO:0015721; bile acid and bile salt transport | 9.642E-06 | 3.499E-03 | NR1H4, SLCO1B1, SLCO1B3 |
MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.813E-05 | 9.007E-03 | CA1, CA2 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.795E-23 | 3.043E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.056E-21 | 4.601E-18 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
CC | GO:0044425; membrane part | GO:0001518; voltage-gated sodium channel complex | 1.523E-17 | 4.145E-14 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
MF | GO:0005215; transporter activity | GO:0005248; voltage-gated sodium channel activity | 1.079E-15 | 2.136E-12 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
BP | GO:0009987; cellular process | GO:0019228; neuronal action potential | 8.904E-15 | 1.491E-11 | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN8A, SCN9A |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.140E-29 | 6.593E-28 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.406E-06 | 2.526E-05 | SLCO1B1; CA2; SLCO1B3; NR1H4 |
hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 1.876E-04 | 1.313E-03 | SCN9A; SCN2A; SCN3A |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.363E-04 | 2.291E-03 | CA2; CA4 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 7.459E-04 | 3.133E-03 | AKR1B10; GAA |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | SCN1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | SCN1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | SCN1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nervous and musculoskeletal disorders | R25-R29 | SCN4A |
G00-G99: Diseases of the nervous system G00-G99 | Peripheral neuropathy | G64 | SCN1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | SCN1A |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | SCN1A; HCAR2 |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | SCN1A |
I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | SCN1A |
C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9 |
C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | SCN1A |
I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | SCN1A |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | SCN9A |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
G00-G99: Diseases of the nervous system G00-G99 | Seizures occurring during or following neurosurgery | G40 | SCN1A |
I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | SCN1A |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | SCN1A |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | SCN1A |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Seizures associated with lennox-Gastaut syndrome | R56.9 | SCN1A |
C00-D49: Neoplasms | Gastric cancer | C16 | SCN1A |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | SCN1A |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | SCN9A; SCN1A; SCN4A |
O00-O9A: Pregnancy, childbirth and the puerperium | Oxytocic | O00-O99 | SCN1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | GPBAR1; HCAR2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | SCN1A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | SCN1A |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | SCN1A; SCN1A |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local or regional analgesia and anesthesia | R20.0 | SCN1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SCN1A |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | SCN1A |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | SCN1A |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | SCN1A |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
G00-G99: Diseases of the nervous system G00-G99 | Seizures | G40, P90, R56 | SCN1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | SCN1A |
NA: NA | Seizure disorder | NA | SCN1A |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | SCN1A |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
A00-B99: Certain infectious and parasitic diseases | Infections with sarcoptes scabiei | B86 | SCN1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SCN1A |